The Effect of CORT118335 on Olanzapine-Induced Weight Gain

Inclusion Criteria: * Body mass index 18.0 to 25.0 kg/m\^2, inclusive * Stable body weight as indicated by assessment at screening and pre-dose * Able to swallow the size and number of tablets required * Provide written informed consent and agree to adhere to study restrictions and contraception requirements. Exclusion Criteria: * Have received any investigational medicine in a clinical research study within the previous 3 months, or CORT118335 at any time * Employee, or immediate family member of a study site or Sponsor employee * Have a pregnant partner * History of abuse of any drug or alcohol, or regularly consume more than 21 units alcohol/week * Smokers or users of e-cigarettes and nicotine replacement products within the last 6 months * Clinically significant abnormal results of clinical laboratory safety tests, electrocardiogram, or measurement of heart rate and blood pressure * History of clinically significant cardiovascular, renal, hepatic, endocrine, metabolic, respiratory, or gastrointestinal disease, neurological or psychiatric disorder * History of jaundice or gallstones or had a cholecystectomy * Family history or known risk for narrow angle glaucoma * Consumed liquorice or other glycyrrhetic acid derivatives regularly in the past 6 months * Any condition that could be aggravated by glucocorticoid and/or mineralocorticoid antagonism (e.g., asthma, any chronic inflammatory condition, postural hypotension/orthostatic symptoms) * Presence or history of clinically significant allergy * Donation or loss of greater than 400 mL of blood within the previous 3 months * Are taking, or have taken, any prescribed or over-the-counter drug within 14 days other than paracetamol or standard dose multivitamins. Longer restrictions apply for some medicines. * Lactose intolerance. NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.